# TAU G272V Research Report **Protein:** TAU G272V **Variant:** G272V **UniProt ID:** P10636 **Disease Association:** Alzheimer's disease **Report Generated:** 2026-07-29 21:38 UTC **AlphaFold Confidence (pLDDT):** 55.0% **Structure Folded:** 2026-07-25 --- ## Structure Summary The G272V mutation in tau protein, associated with Alzheimer's disease, was analyzed using computational structure prediction methods. The resulting model shows an average confidence score of 55.0 (on a 0-100 scale), indicating substantial structural uncertainty that limits reliable interpretation of how this mutation affects tau's three-dimensional shape. This low confidence suggests that experimental studies, rather than computational predictions alone, will be needed to understand how G272V contributes to disease. --- Tau is a protein that normally stabilizes microtubules (the cell's structural scaffolding) in neurons, but in Alzheimer's disease, abnormal tau forms tangled aggregates that damage brain cells [2][3]. The G272V mutation replaces a small, flexible glycine amino acid with a larger valine at position 272 of the tau protein. Understanding how such mutations alter tau's structure could reveal why some people develop early-onset or aggressive forms of disease. This analysis used AlphaFold2-based computational methods to predict the three-dimensional structure of tau carrying the G272V mutation. However, the average confidence score (pLDDT) of 55.0 falls well below the threshold of 70 typically considered reliable for structural interpretation. This low confidence likely reflects tau's intrinsically disordered nature—the protein lacks a stable, fixed structure under normal conditions, making computational predictions particularly challenging. Without high-confidence structural data, we cannot reliably determine whether G272V causes specific local structural changes or affects tau's flexibility. The broader research context suggests that tau mutations drive disease through multiple mechanisms. Patient-derived studies show that pathological tau can propagate between neurons and form mature tangle pathology characteristic of Alzheimer's disease [2]. Neurofibrillary tangles containing abnormal tau correlate strongly with cognitive decline, and their distribution patterns differ across disease variants [3]. Recent genetic studies have identified both common and rare variants affecting tau deposition in the brain [5], while therapeutic approaches targeting tau pathology and related genetic risk factors like APOE4 are under active development [1][4]. Given the low structural confidence for this G272V model, experimental approaches will be essential to understand this variant's effects. Techniques such as X-ray crystallography, cryo-electron microscopy of tau fibrils, or biophysical studies of aggregation kinetics could provide reliable data on whether G272V promotes the abnormal tau assembly seen in Alzheimer's disease. The mutation's position and chemical change (glycine to valine) suggest potential effects on local protein flexibility, but such hypotheses require experimental validation rather than relying on uncertain computational predictions. ## Works Cited [1] Kim et al. (2026). Therapeutic Gene Editing of APOE4 in Sporadic Alzheimer's Disease via Prime Editor 7. Advanced science (Weinheim, Baden-Wurttemberg, Germany). [PubMed](https://pubmed.ncbi.nlm.nih.gov/42467931/) [2] Ji et al. (2026). Patient-derived tau-seeded human neuronal chimeras recapitulate mature Alzheimer's tau pathology and uncover human-specific neuronal vulnerability. bioRxiv : the preprint server for biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42465485/) [3] Smirnov et al. (2026). Neurofibrillary tangle distribution in posterior cortical atrophy and typical early-onset Alzheimer's Disease. Free neuropathology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42453899/) [4] Zemke et al. (2026). The NORAD -pumilio regulatory axis links lncRNA dysregulation to tau propagation-associated phenotypes. bioRxiv : the preprint server for biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42427771/) [5] Gunasekaran et al. (2026). Common and rare variant analyses implicate JARID2 in cerebral tau deposition. NPJ dementia. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42404994/) ## Similar Research **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **Protein quality control systems in neurodegeneration - culprits, mitigators, and solutions?** Ciechanover et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40969213/) **Melatonin-Mediated Nrf2 Activation as a Potential Therapeutic Strategy in Mutation-Driven Neurodegenerative Diseases.** Inigo-Catalina et al. (2025) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41154499/) **Alzheimer's Disease Continuum: Evaluating the Relationship between Fluid Biomarkers and Patients' Phenotype and Profile.** Gerlando et al. (2026) *Relevant to Alzheimer's disease research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/41619269/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | frontotemporal dementia | 0.789 | genetic_literature, clinical, literature, genetic_association, animal_model | | Pick disease | 0.757 | literature, animal_model, genetic_association, genetic_literature | | supranuclear palsy, progressive, 1 | 0.725 | literature, animal_model, genetic_association, genetic_literature | | Progressive supranuclear palsy - parkinsonism | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Atypical progressive supranuclear palsy | 0.715 | literature, animal_model, genetic_association, genetic_literature | | Classical progressive supranuclear palsy | 0.696 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy-parkinsonism syndrome | 0.647 | animal_model, genetic_association, genetic_literature | | late-onset Parkinson disease | 0.639 | literature, animal_model, genetic_association, genetic_literature | | semantic dementia | 0.639 | literature, animal_model, genetic_association, genetic_literature | | progressive supranuclear palsy | 0.614 | genetic_literature, clinical, literature, genetic_association, animal_model | *...and 3339 more associations* --- ## Agent Findings ### Literature (1) - **2026-07-25:** None of the provided papers are directly relevant to understanding the TAU G272V variant specifically. While several papers address tau pathology, phosphorylation, genetics, and MAPT regulation in Alzheimer's disease, none examine the G272V missense mutation at position 272 of the tau protein or its functional consequences. ### Clinical (1) - **2026-07-25:** ### Structural (1) - **2026-07-26:** AlphaFold structure update: Baseline check: 9 structure(s) found ### Synthesis (1) - **2026-07-26:** Synthesis of 5 findings (clinical, literature, peptides, structural, supplements): The TAU G272V variant in Alzheimer's disease currently exists in a significant translational gap bet... --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)